Annexon, Inc. (NASDAQ:ANNX – Get Free Report) has earned a consensus rating of “Buy” from the six analysts that are currently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $15.80.
ANNX has been the topic of a number of analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a research report on Monday, September 9th. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Annexon in a research report on Tuesday, August 13th. Finally, Needham & Company LLC restated a “buy” rating and issued a $16.00 target price on shares of Annexon in a research report on Tuesday, August 13th.
View Our Latest Report on ANNX
Insider Buying and Selling at Annexon
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in ANNX. BVF Inc. IL purchased a new position in Annexon in the fourth quarter valued at about $31,780,000. Bain Capital Life Sciences Investors LLC raised its position in Annexon by 41.4% in the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 8,061,719 shares of the company’s stock valued at $36,600,000 after purchasing an additional 2,359,793 shares during the period. Bellevue Group AG purchased a new position in Annexon in the first quarter valued at about $15,647,000. Candriam S.C.A. purchased a new position in Annexon in the second quarter valued at about $10,061,000. Finally, Vanguard Group Inc. raised its position in Annexon by 96.4% in the first quarter. Vanguard Group Inc. now owns 3,747,655 shares of the company’s stock valued at $26,871,000 after purchasing an additional 1,839,329 shares during the period.
Annexon Stock Performance
Shares of Annexon stock opened at $7.03 on Thursday. Annexon has a one year low of $1.57 and a one year high of $8.40. The company has a market cap of $649.66 million, a price-to-earnings ratio of -4.78 and a beta of 1.28. The business’s 50 day moving average price is $6.05 and its 200 day moving average price is $5.58.
Annexon (NASDAQ:ANNX – Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.23) EPS for the quarter, hitting analysts’ consensus estimates of ($0.23). On average, analysts predict that Annexon will post -0.97 EPS for the current fiscal year.
About Annexon
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
See Also
- Five stocks we like better than Annexon
- Bank Stocks – Best Bank Stocks to Invest In
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Utilities Stocks Explained – How and Why to Invest in Utilities
- MarketBeat Week in Review – 9/16 – 9/20
- Health Care Stocks Explained: Why You Might Want to Invest
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for Annexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annexon and related companies with MarketBeat.com's FREE daily email newsletter.